Category Archives: Clinical Cardiology

4DMT has made tremendous progress since the close of our Series C financing. We have advanced product candidates across our key therapeutic areas of ophthalmology, cardiology and pulmonology, including the initiation of the clinical programs for 4D-110 and 4D-125 in ophthalmology, and 4D-310 for the treatment of Fabry disease, said David Kirn, M.D., co-founder and chief executive officer of 4DMT. With the addition of Robert Fishman, Raphael Schiffmann and Robert Kim to our clinical R&D leadership team, 4DMT gains not only extensive experience in clinical development and translational medicine, but also unique and specific experience within each of the initial 4DMT therapeutic areas. Continue reading →

Jon Zwinski succeeds Ken McBean as company advances global therapeutic efforts CARY, N.C., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Chiesi, USA (Formerly Known As Cornerstone Therapeutics)(key-ay-zee), the U.S. Continue reading →

This article was originally published here J Womens Health (Larchmt). 2020 Nov 27 Continue reading →

Repeat catheter ablation was found to be safe and to have efficacy comparable with index ablation in alleviating symptoms in patients with atrial fibrillation (AF), according to a study published in Clinical Research in Cardiology. Despite standardized pulmonary vein isolation during index ablation, arrhythmia recurrence caused by reconnected pulmonary veins, often indicates the need for repeat procedure. Continue reading →

1 December 2020 Julia Bakker The British Heart Foundation has paid tribute to the life and work of Professor Tony Gershlick, who sadly died on Friday the 20th of November 2020 after contracting Covid-19. Professor Gershlick was a Consultant Cardiologist at Glenfield Hospital and Professor of Interventional Cardiology at the University of Leicester. Continue reading →

MitraClip Guide delivery achieved in under 7.5 minutes1 TORONTO, Dec. 1, 2020 /PRNewswire/ -A recentpublicationdemonstratedprocedural efficiencyforMitraClip transcatheter mitral valve repair (TMVR)with use of theVersaCrossRF Transseptal Solution, reportingguide deliveryfrom femoral accessin under7.5minutes1. Continue reading →

This article was originally published here Cardiology. 2020 Nov 25:1-8. doi: 10.1159/000511128 Continue reading →

CARLSBAD, Calif., Nov. 30, 2020 /PRNewswire/ --Ionis Pharmaceuticals, Inc., (NASDAQ: IONS) today announced that the biopharmaceutical companyAstraZeneca hasinitiated a Phase 2b clinical trial of ION449 (AZD8233),an investigational antisense medicine designed to reduce blood cholesterol levels in patients with dyslipidemia by targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), an important regulator of low-density lipoprotein cholesterol (LDL-C). PCSK9 is an enzyme that controls the number of LDL receptors on the surface of cells Continue reading →

Professor/Associate Professor/Assistant Professor in Cardiology in the Department of Veterinary Clinical Sciences[Ref. Continue reading →

Market Growth Insight has presented updated research report on Precision Medicine, Point of Care Devices, Molecular Diagnostics, and Interventional Cardiology Market, offering insightful information like market share, market size, and growth rate during the forecast period 2020 2026 that are precisely projected based on type, application, sales channel, and region. The Precision Medicine, Point of Care Devices, Molecular Diagnostics, and Interventional Cardiology report further described key segments of the market to help business, marketing executives, and customers know the current as well as upcoming products and improvements. The Precision Medicine, Point of Care Devices, Molecular Diagnostics, and Interventional Cardiology report is also beneficial to stakeholder to plan their future investment with the help of information on current company statuses mentioned in the report Continue reading →